Exchange: NASDAQ·Updated 07:30 PM EST

TVRD News

News
all
press releases
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.
Zacks
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
Tvardi Therapeutics stock jumps this week as phase I data for TTI-109 highlight improved tolerability, target engagement and support plans for mid-stage development.
Zacks
More News
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics (NASDAQ:TVRD)read more...
Benzinga
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics (NASDAQ:TVRD)read more...
Benzinga
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors...
PR Newswire
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. (Tvardi or the Company) (NASDAQ: TVRD). This press release features...
Business Wire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf...
PR Newswire
Tvardi (TVRD) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks
Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat...
Business Wire
Tvardi Therapeutics, Inc. (Tvardi) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat...
Business Wire
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc.. (Tvardi or the Company) (NASDAQ: TVRD). Faruqi & Faruqi is a leading...
Business Wire

Advertisement|Remove ads.